Sign up
Pharma Capital

CV Sciences Inc, a cannabinoid revenue maker that stands out among pot stocks

Proactive Investors contributor Bob Byrne tells Proactive's Christine Corrado he's impressed by CV Sciences (OTCQB: CVSI), as the $289 million life sciences company has reported record sales, gross profit, and net income.

Byrne says the stock is already up more than 400% on a year-to-date basis, but given the company’s incredible financial performance and its chances to be up-listed to the Nasdaq, the share price gains shouldn’t come as a surprise.


View full CVSI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.